STAT January 6, 2025
Adam Feuerstein

Readouts are coming from Ultragenyx, Akero Therapeutics, and Incyte

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

Osteogenesis imperfecta, or OI, is a group of genetic disorders characterized by decreased bone mass and increased bone fragility. Ultragenyx is developing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Trendspotting: Predictions for Bio-IT World in 2025
The Future of Cancer Drug Development: Advancements, Challenges, and the Transformative Role of AI
Fierce Biotech Fundraising Tracker '25: Alebund adds $75M; XyloCor raises $67M
J&J says its lung cancer drug combination keeps people alive longer
How GLP-1s Are Showing Up at CES 2025

Share This Article